Background: Previous studies demonstrated that prognosis of germline deficiency in mismatch repair protein (dMMR) was different from that of sporadic dMMR. The underlying mechanism has not been studied. Methods: From a prospectively maintained database, we collected dMMR colorectal cancer (CRC) patients identified by postoperative immunohistochemistry screening. According to genetic test, patients were grouped as Lynch-associated or sporadic dMMR. We compared the clinical-pathological features, prognosis, and immunoreactive differences between the two groups. By whole-exome sequencing and neoantigen detection pipeline, mutational frequencies and neoantigen burdens were also compared. All statistical tests were two-sided. Results: Sixty-seven sporadic dMMR and 85 Lynch-associated CRC patients were included in the study. Sporadic dMMR patients were older (P < .001) and their tumors were poorly differentiated (P ¼ .03). The survival was better in the Lynch-associated group (P ¼ .001). After adjustment, the difference still remained statistically significant (hazard ratio ¼ 0.29, 95% confidence interval ¼ 0.09 to 0.95, P ¼ .04). The scores of Crohn's-like reaction (CRO; P < .001), immunoreactions in the invasive margin (IM; P ¼ .01), tumor stroma (TS; P ¼ .009), and cancer nest (CN; P ¼ .02) of the Lynch-associated group were statistically significantly higher. The numbers of CD3þ, CD8þ, Foxp3þ tumor-infiltrating lymphocytes (TILs) in IM; CD3þ, CD4þ TILs in TS; and CD3þ, CD4þ, CD8þ TILs in CN were statistically significantly higher in Lynch-associated dMMR patients. Based on the 16 patients who under went whole-exome sequencing, there were also more somatic mutations and neoantigen burdens in the Lynch-associated group compared with the sporadic dMMR group (439/pt vs 68/pt, P ¼ .006; 628/pt vs 97/pt, P ¼ .009). Conclusions: There are heterogeneities in dMMR CRCs. Lynch-associated dMMR patients present with more somatic mutations and neoantigens compared with sporadic dMMR, which probably results in stronger immunoreactions and survival improvement.
Previous studies have found two different molecular mechanisms of colorectal cancer (CRC): chromosomal instability and microsatellite instability (MSI) (1) . Most CRCs (50%-60%) show chromosomal instability. MSI CRCs display inactivation of DNA mismatch repair (MMR) genes due to mutations or transcriptional silencing, which leads to loss of expression in MMR proteins (dMMR) and causes accumulation of DNA microsatellite errors. Compared with proficient mismatch repair (pMMR), dMMR CRCs have distinct pathological features: often locating in the proximal colon, poorly differentiated or mucinous adenocarcinoma, and increased number of tumorinfiltrating lymphocytes (TILs) (2, 3) . Above all, it is widely established that dMMR CRC patients enjoy a better prognosis (4) (5) (6) (7) .
According to the status of germline mutation on MMR genes, dMMR CRCs could be divided into Lynch syndrome-associated dMMR, accounting for 3% to 5% of all CRCs, and sporadic dMMR, usually caused by hypermethylation of CpG islands surrounding the promoters of MLH1, accounting for about 15% of all CRCs (8, 9) . We define "Lynch-associated dMMR" as MMR deficiency caused by pathogenic or likely pathogenic germline mutations in MMR genes. Several studies have investigated the differences in clinical-pathological features (10, 11) , chemotherapy sensitivity, and prognosis (12) (13) (14) between sporadic and Lynch-associated dMMR CRCs. It was reported that patients with Lynch-associated dMMR presented better survival and were more sensitive to chemotherapy (12, 14, 15) . The underlying mechanism leading to the prognostic difference has not been illustrated.
We hypothesized that immune response might play an important role in the prognostic discrepancy between sporadic and Lynch-associated dMMR. We retrospectively investigated the clinical-pathological differences between Lynch-associated and sporadic dMMR CRCs. In addition, tumor immune responses, somatic mutations, and neoantigen burdens in the two populations were also explored.
Methods

Study Design
From a prospectively maintained universal dMMR screening database, patients with dMMR CRCs and who received Hereditary Colorectal Cancer Genetic Testing were enrolled in the study. The testing, which included 14 genes (namely, MLH1, MLH3, MSH2, MSH6, PMS1, PMS2, APC, AXIN2, STK11, EPCAM, PTEN, SMAD4, MUTYH, BMPR1A), was carried out in the Molecular Diagnostics Department of our center by Illumina Hiseq 2000 (Illumina, San Diego, CA; target sequence capture and next-generation sequencing) using EDTA anticoagulated peripheral blood.
The BRAF V600E mutation status was determined by using a commercially available kit (Qiagen, Valencia, CA) according to the manufacturer's instructions; pyrosequencing analysis was used to confirm positive mutations. Methylation of the promoter region of MLH1 was performed as previously reported (16) . According to genetic testing, as well as BRAF V600E mutation and MLH1 methylation tests, patients were divided into two groups, namely Lynch-associated and sporadic dMMR. We compared the clinical-pathological differences between these two groups. By evaluating the hematoxylin and eosin (HE) staining slides, immunohistochemistry (IHC), whole-exome sequencing (WES), and neoantigen discovery pipeline, we also investigated the differences in immune responses, lymphocyte subsets, somatic mutational load, and neoantigen burdens. All patients signed consent forms for using specimens for scientific use, and we obtained permission from the Ethics Committee of Sun Yat-Sen University Cancer Center for our study.
Grouping
The detailed grouping criteria were as follows:
Lynch-Associated dMMR Patients with pathogenic or likely pathogenic germline mutations in MMR genes (MLH1, MSH2, MSH6, PMS2) detected by genetic testing were considered Lynch-associated dMMR (17, 18 ARTICLE defined according to the American College of Medical Genetics and Genomics recommendations (19) .
Sporadic dMMR
Patients without germline mutations were considered sporadic dMMR, as well as those with BRAF V600E mutation or MLH1 promoter hypermethylation.
Data Collection
We constructed a database and collected the following information of patients 
Evaluation of the Immune Response
Hematoxylin and Eosin Staining Two pathologists unaware of other data evaluated the HE-stained slides of the grouped patients independently. Four immunoreactions were examined: Crohn's-like reaction (CRO), immunoreactions in the invasive margin (IM), in the tumor stroma (TS), and cancer nest (CN). CRO was defined as transmural lymphoid aggregates within the muscularis propria or pericolic fibroadipose tissue with the appearance of a germinal center. IM was defined as discrete lymphoid reactions in the invasive margin of tumor. TS was defined as lymphocytic reaction in tumor stroma within the tumor mass. CN was defined as lymphocytes in the cancer nests (Supplementary Figure 1 , available online). According to previous reports (20) (21) (22) (23) , a semiquantitative score was applied to assess the immunoreactions. Absent, slight, moderate, and notable immunoreactions were scored with 0, 1, 2, and 3 points, respectively. The total immunoreactions score was the sum of the four scores.
Immunohistochemistry
The primary monoclonal antibodies used were labeled in Supplementary Table 1 (available online); the secondary was antirabbit/mouse IgG monoclonal antibody (DAKO Real Envision, Santa Clara, CA). IHC was conducted according to Envision's two steps in the light of the manufacturer's instructions.
Lymphocyte Count
Lymphocytes were counted by a pathologist unaware of other information in a high-power field (HPF; 400Â, 0.028 mm 2 , Olympus BX41, Tokyo, Japan) according to the following method: select five HPFs in the invasive margin, tumor stroma, and cancer nest; count the positive cells; and take the average.
Whole-Exome Sequencing
Chromosomal DNA was extracted from frozen fresh cancer tissue along with a matched blood sample using the Qiagen DNA formalin-fixed, paraffin-embedded tissue kit or Qiagen DNA blood mini kit (Qiagen, Valencia, CA). Genomic DNA from tumor and normal samples were fragmented and used for Illumina TruSeq library construction (Illumina, San Diego, CA) according to the manufacturer's instructions. Exons were captured using the Agilent SureSelect v.4 kit (50 M) according to the manufacturer's instructions (Agilent, Santa Clara, CA). After six cycles of polymerase chain reaction, the amplified library was purified using the NucleoSpin Extract II purification kit (Macherey-Nagel, PA) following the manufacturer's instructions. The captured library was sequenced using Illumina HiSeq 2500 (V4 PE2 Â 100 seq) instrumentation (Illumina, San Diego, CA); the designed sequencing depth of the tumor was two times that of the normal sample.
Primary sequence data for both tumor and normal samples were processed by BWA software using hg19 (from UCSC, https://genome.ucsc.edu/) as the reference genome sequence. Somatic mutations were detected with the BWA picard þ GATK þ mutect þ annovar pipeline. We identified somatic mutations by comparing the tumor data with the matched normal tissue using the following quality control standards: 1) the number of allele mutations in the tumor was less than five or the ARTICLE frequency of allele mutations was less than 5%, or the number of allele mutations in the normal tissue was more than three or the frequency of allele mutations was more than 3%; 2) the P value of the allele mutation frequency by the Fisher exact test was less than .01; 3) the population-based mutation frequency was less than 0.01%. Somatic single nucleotide variations (SNVs) and short segments' insertion/deletion (Indels) that were predicted to result in amino acid changes were annotated.
Neoantigen Discovery Pipeline
Somatic mutations (including SNVs and Indels) predicted to result in amino acid changes were analyzed in a neoantigen discovery pipeline (Supplementary Figure 2, individual patient were determined by Polysolver 1.0 (24). Afterwards, amino acid fragments with lengths of 15 aa, 17 aa, and 19 aa were used to identify 8 mer, 9 mer, and 10 mer epitopes using the epitope prediction server NetMHCpan 3.0 (25, 26) . Epitopes with a predicted affinity of less than 500 nm were considered potential neoantigens. 
Results
Patient Demographics
One hundred fifty-two patients who fulfilled the aforementioned criteria were included in the study (Figure 1 ). The demographics of the 85 Lynch-associated and 67 sporadic dMMR patients are detailed in Table 1 The median age of Lynch-associated and sporadic dMMR patients was 51 years (range ¼ 22-76 years) and 67 years (range ¼ 28-84 years), respectively. Patients with Lynch-associated dMMR were statistically significantly younger than those with sporadic dMMR (P < .001). Poorly differentiated or mucinous adenocarcinoma was more common in sporadic dMMR (65.7% vs 47.1%, P ¼ .03). There was no statistically significant difference in tumor location. More than half of the patients were stage II, while patients with stage IV were relatively rare. Three Lynchassociated dMMR patients were diagnosed as peritoneal metastases intra-operatively; they received palliative surgery (two ileostomy and one palliative colectomy) and subsequent chemotherapy. Operable liver metastases were detected by preoperative computed tomography scan in two patients (one for each group), and both of them received colectomy and liver resection with curative intent.
Survival Analysis
Until the last visit, 23 of the 152 patients (15.1%) died. The median surveillance time was 44 months (range ¼ 10-70 months). Overall survival was used to assess the patients' prognosis. Figure 2A showed the Kaplan-Meier estimates for Lynchassociated and sporadic dMMR patients. Statistically significant predictors for the death were summarized in Supplementary Figure 3 (available online). 
Immunoreactions Rate
One hundred forty-three patients (82 Lynch-associated, 61 sporadic dMMR; slides of nine patients were not suitable for scoring because rating areas were missing) had intact evaluable HEstained specimens. The immunoreaction scores of each region and typical pictures are illustrated in Figure 3 and Supplementary Figure 4 (available online). The scores of CRO (P < .001), IM (P ¼ .01), TS (P ¼ .009), and CN (P ¼ .02) were statistically significantly higher in Lynch-associated dMMR patients compared with sporadic dMMR patients. The overall survival of patients with total immunoreaction scores higher than 5 was statistically significantly better (HR ¼ 0.18, 95% CI ¼ 0.06 to 0.52, P ¼ .002) ( Figure 2B ).
Immunohistochemistry Staining of TILs
Immunohistochemistry staining was performed in the abovementioned patients (82 Lynch-associated, 61 sporadic dMMR). The results are shown in Figure 4 and Table 3 . The numbers of CD3þ, CD8þ, Foxp3þ TILs in IM; CD3þ, CD4þ TILs in TS; and CD3þ, CD4þ, CD8þ TILs in CN were statistically significantly higher in Lynch-associated dMMR patients. Typical positive stained TILs were displayed in Supplementary Figure 5 (available online).
Whole-Exome Sequencing Results
In order to evaluate the impact of tumor mutational load, 16 patients (eight in each group) were randomly selected for whole-exome sequencing ( Table 4) . The total reads, coverage rate, and depth of each patient are demonstrated in Supplementary Figure 6 and Supplementary Table 3 (available  online) .
After filtrations by the abovementioned criterions, 3702 SNVs and 353 Indels that led to amino acid changes were detected. The somatic mutation number of each patient is labeled in Table 4 . The average somatic mutation number was statistically significantly higher in Lynch-associated dMMR compared with sporadic dMMR (439/pt: median ¼ 384, range ¼ 65-1079; vs 68/pt: median ¼ 71, range ¼ 43-88, P ¼ .006).
Neoantigen Burden
Using NetMHCpan, epitopes with a predicted affinity of less than 500 nm were selected and calculated (26) . The number of 8 mer, 9 mer, and 10 mer and total epitopes of each patient and corresponding HLA-I types are listed in Table 4 . Lynchassociated dMMR had statistically significantly higher neoantigen burden (628/pt: median ¼ 496, range ¼ 109-1910; vs 97/pt: median ¼ 102, range ¼ 26-161, P ¼ .009).
By Spearman rank correlation test, the neoantigen burden increased with the addition of somatic mutation (r s ¼ 0.77, P ¼ .001; data not shown).
Discussion
The current study demonstrates that Lynch-associated dMMR patients had a better prognosis. Further study shows that patients with Lynch-associated dMMR present with stronger immune response, higher mutational load, and more neoantigens than patients with sporadic dMMR, which may explain the discrepancy in prognosis in these two populations. To our knowledge, this had not been reported before.
It is well established that lymphocyte infiltration into cancer nests or stroma, or tertiary lymphoid structures such as the Crohn's-like reaction, confers a survival advantage (20, 23, 27, 28) . The type, density, and location of immune cells determine the way they work and are valuable prognostic factors as well (29) (30) (31) (32) (33) immunoreactions have been found in familial MSI CRC previously (11, 37) . However, cell count based on a specific subtype of lymphocytes and localization was not evaluated. The current study demonstrates that the numbers of CD3
þ lymphocytes in IM of Lynch-associated patients were statistically significantly more than those of sporadic patients, which may explain the improved prognosis in patients with Lynch-associated dMMR. Compared with MMR proficiency, it has been reported that in patients with dMMR the stronger immunoreactions and more TILs are associated with higher levels of mutational load and neoantigens, which result in improved prognosis (38) . Furthermore, our study found that there was heterogeneity among dMMR CRCs, as demonstrated by the fact that mutational load and secondary neoantigens were statistically significantly greater in patients with Lynch-associated dMMR. The current study suggests that mutational load and neoantigens are the intrinsic reasons for stronger immunoreactions and improved survival in Lynch-associated dMMR.
The explanation of germline dMMR CRCs' higher mutational load is not clear. We raised several possible mechanisms. First, 
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inactivation of tumor suppressor genes and/or activation of oncogenes lead to tumor genesis. It is a multistep process with accumulation of mutations. We hypothesize that there might be a threshold. For patients with dMMR CRCs, deficiencies in the mismatch system cause errors to accumulate during DNA replication and accelerated tumor genesis. In addition, hypermethylation is widespread and accumulates in genomes, which causes epigenetic changes but without changing the gene sequences. Consequently, the genetic changes (mutations) needed to reach the "threshold" might be relatively fewer in sporadic dMMR CRCs. Second, sporadic dMMR is highly accompanied by the BRAF V600E mutation, which results in activation of signaling pathways of proliferation and accelerates tumor genesis. As a result, accumulation of mutations might be lower. Series of mutations are involved in tumor genesis and progress. Mutations happening in exons can result in amino acid or protein changes. When the changed amino acid sequence binds to the antigen-binding grooves of HLA-I, a potential neoantigen is born. The fact that tumors with a higher mutational load also have more neoantigen burdens supports this hypothesis. Based on this theory, computational systems for large-scale identification of predicted new antigens have been raised and accepted widely (24, 39, 40) .
However, the actual immunoreactions initiated by mutations are much more complex, because of the tumor's immune escape mechanism, like downregulation of HLA-I, induction of regulatory T cells (Tregs), or expression of immunosuppressive molecules such as PD-1, which explains why tumor cells are not eliminated by effective immune response. Two promising applications against these escape mechanisms are cancer vaccine design and checkpoint immunotherapy. Although only a tiny portion of predicted neo-epitopes is efficacious in targeting T cells (41) , these antigens generated from somatic mutation are a very good source of tumor vaccines with lower immune tolerance (42, 43) . Recent immunotherapy advances like inhibition of immune regulatory checkpoints with anti-PD-1 antibodies has shown promising efficacy in MSI-H CRCs (44) . The authors suggested that the greatly increased number of mutationassociated neoantigens resulting from mismatch-repair deficiency was the basis for the enhanced anti-PD-1 responsiveness. Further clinical trials are needed to verify the treatment response and somatic mutation differences between germline and sporadic dMMR CRCs.
There were several limitations in the present study. First, Lynch-associated patients accounted for more than half in the present study, which does not correspond to the population-based data (37) . The major reason was that our study was not a study with consecutive cases. DMMR patients with hereditary indications like young age, multiple malignancies, and family history were more likely to undergo genetic testing, which might result in selection bias. Second, it should be noted that the somatic mutations and mutationassociated neoantigens in our study were relatively low compared with the MSI-H patients in the abovementioned trial (40) . One possible explanation was divergence of the somatic mutation screening criteria. Furthermore, we tentatively put forward that dMMR CRCs might have a wide range of somatic mutational load in the current data. The number of patients who underwent WES and neoantigen prediction was limited in the abovementioned (40) and our study. Third, the ranges of somatic mutations and mutation-associated neoantigens for Lynch-associated cases were quite wide; it was difficult to give a definite explanation due to the small sample size. We supposed that patient age might also play a role considering the fact that the two Lynch-associated patients with the highest mutation burden were all older than age 60 years, while patients with lower mutation burdens were much younger. Further studies are needed to evaluate this hypothesis and explore the possible reasons.
In conclusion, there are heterogeneities in dMMR CRCs. Lynch-associated dMMR has a better prognosis and stronger immunoreactions, which may be explained by higher mutational loads and more neoantigens. Further studies are needed to verify the treatment response between germline and sporadic dMMR CRCs.
